Literature DB >> 1750633

The efficacy of antivenom in prevention of cardiovascular depression and coagulopathy induced by brown snake (Pseudonaja) species venom.

J Tibballs1, S Sutherland.   

Abstract

The efficacy of antivenom in prevention of cardiovascular depression and coagulopathy induced by Brown Snake species (Pseudonaja textilis, Pseudonaja affinis) was investigated in anaesthetised mechanically ventilated dogs. Venom and antivenom in variable amounts were incubated together at 37 degrees C for 30 minutes prior to intravenous injection. The dose of antivenom required to prevent severe cardiovascular depression and coagulopathy induced by Pseudonaja textilis venom was 25 times the current recommended dose for clinical use. A tenfold dose of antivenom was required to neutralise similar effects induced by Pseudonaja affinis venom. Large amounts of antivenom may be required in clinical use if coagulopathy or cardiovascular depression are present after envenomation by species of the Brown Snake genus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1750633     DOI: 10.1177/0310057X9101900407

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Venom yields from Australian and some other species of snakes.

Authors:  Peter J Mirtschin; Nathan Dunstan; Ben Hough; Ewan Hamilton; Sharna Klein; Jonathan Lucas; David Millar; Frank Madaras; Timothy Nias
Journal:  Ecotoxicology       Date:  2006-08-26       Impact factor: 2.823

2.  Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14).

Authors:  George E Allen; Simon G A Brown; Nicholas A Buckley; Margaret A O'Leary; Colin B Page; Bart J Currie; Julian White; Geoffrey K Isbister
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

3.  Dosage comparison of snake anti-venomon coagulopathy.

Authors:  Ali Hassan Rahmani; Amir Jalali; Mohammad Hassan Alemzadeh-Ansari; Mina Tafazoli; Fakher Rahim
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.